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ABSTRACT 
Background and objectives 
      Among all the neurological diseases of adult life, the cerebrovascular 
ones clearly rank the first in frequency and importance. At least 50% of the 
neurological disorders in a general hospital are of this type. Stroke, after heart 
disease and cancer is one of the most common causes of death. 
Uric acid is the most abundant aqueous antioxidant in humans, and 
contributes as much as two-thirds of all free radical scavenging capacity in 
plasma. A number of major epidemiological studies have identified high 
UA concentrations as an important risk marker for stroke in unselected 
populations. There is a pressing need to identify additional treatable risk 
factors for stroke that are easily measured and highly prevalent in the 
general population. Hyperuricemia is one such potential risk factor. This 
study aims at finding the relationship between serum uric acid levels at 
presentation and the clinical outcome following acute ischemic stroke so 
that appropriate intervention can be targeted to reduce the risk and improve 
the outcome following acute stroke. 
Methods 
Patients admitted in general wards of  Department of Medicine, Madras 
Medical  College, Chennai, with  acute ischemic stroke  during the period of 
April 1st 2016 to September 31st 2016 were taken up for study considering the 
inclusion and exclusion criteria. 
Results 
 Majority of this stroke population were between 61 to 70yrs old. 
Hypertension constituted the major risk factor in this stroke population 
followed by Diabetes mellitus, smoking, CAD, and dyslipidemia for 
hypertension and male sex. Overall 63% 0f patients had bad outcome (39 out of 
60). Among them 92% (34 out of 39) had high serum uric acid levels. When 
serum uric acid levels were correlated with outcome at 7 days it was found to 
be associated with poor outcome. 
Interpretation and conclusion 
 Hypertension, Diabetes mellitus, smoking, CAD, and 
dyslipidemia were the most important risk factors associated with stroke. 
Hypertension and male sex were significantly associated with serum uric acid 
levels in stroke patients. Elevated uric acid level was associated with poor 
outcome among stroke patients at 7 days follow up period. 
Key words; cerebrovascular accident, serum uric acid, anti-oxidants, ischemia, 
prognosis Hypertension, outcome 
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INTRODUCTION 
Uric acid is found to be an abundant anti oxidant in plasma having its 
role in eliminating hydroxyl and superoxide radicals in the tissues. It is also 
proved to be having pro oxidant properties in the absence of other related anti 
oxidants.Hence a detailed study regarding its role is necessary in the etiology 
of various vascular events. 
    Uric acid levels and its role in endothelial dysfunction, dyslipidemia, 
diabetes, CAD, Stroke and Metabolic syndrome are under study around the 
world. Our study is based on its association with outcome in ischemic stroke 
patients. Stroke ranks next to Heart disease and Cancer as the leading cause of 
death. Hence its of prime importance in fixing its role in vascular events. 
            In ischemic stroke patients serum uric acid levels were assessed at the 
time of presentation and patients are followed up for next seven days for 
assessing their outcome based on GLASGOW OUTCOME SCALE. 
Previous larger data involving NHANES study clearly proved an 
independent association between high uric acid levels and poor outcome. 
Hence serum uric acid measurements may play a major role in treatment 
aspects of patients with ischemic stroke in the future.. 
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AIMS AND OBJECTIVES  
To study the association between serum uric acid at presentation and the 
clinical outcome among acute ischemic stroke patients. 
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REVIEW OF LITERATURE 
        Cerebro vascular diseases includes ischemic stroke and hemorrhagic 
stroke accounting for second leading cause of death world wide. A stroke or 
cerebro vascular accident is an abrupt onset of a neurological deficit due to a 
focal vascular cause1  The definition of stroke goes by clinical and laboratory 
studies including brain imaging to support the diagnosis. Generally cerebral 
ischemia is due to reduction in cerebral blood flow that lasts longer thahn 
several seconds, but symptoms are manifested within seconds since neurons 
lack glycogen. If blood flow gets restored quickly symptoms are only transient; 
this is said to be Transient Ischemic Attack(TIA). Hence the definition of TIA 
is neurological symptoms and signs that resolve within 24 hours without any 
evidence of brain infarction on imaging. If Signs & symptoms lasts more than 
24 hours or brain infarction is demonstrated it is said to be a stroke.  
Classification of CerebroVascular Diseases by WHO- 
Cerebral Thrombosis / Embolism – 85% 
1 Cerebral Hemorrhage – 10% 
2 Sub Arachnoid Hemorrhage – 2%  
Hence Ischemic stroke contributes to the most frequent form of stroke. It 
is divided into Thrombotic and Embolic strokes; Thrombotic – 25%; Embolic – 
75% of all ischemic strokes respectively.  
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ANATOMY AND PHYSIOLOGY OF CEREBRAL CIRCULATIONS 
           Brain tissues need continuous adequate blood supply which on its 
cessation for a prolonged time leads to irreparable damage to the brain cells.  
CEREBRAL VESSELS & NORMAL CEREBRAL BLOOD FLOW 
            Brain receives blood from the Basilar artery and Internal Carotid artery. 
Branches of these arteries form CIRCLE OF WILLIS. Venus drainage is by 
sinuses which open into Interal Jugular vein. Brain receives 750ml to 800ml of 
blood/ minute. It is about 15% to 16% of total cardiac output and about 50 to 
55ml/100gm of brain tissue per minute. The cerebral blood flowwhich is higher 
in the first decade of life falls at puberty to adult values. Cerebral blood flow 
decreases from middle age to elderly. Human brain contributes to 2% of the 
total body weight but it receives 15% of cardiac output. This high flow rate 
indicates brain’s high metabolic rate. It consumes about 3.5ml of Oxygen/ 
100gm of Brain tissue/minute. 
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Blood Supply of Relevant Parts of Brain: 
1. Cerebral Cortex 
a) In general, by the cortical branches of the three cerebral arteries. 
b) Motor Area: by the frontal cortical branches of middle cerebral artery    
except for the leg area in the upper part of the pre-central gyrus and 
paracentral lobule and the paracentral cortical branches of the anterior 
cerebral artery (leg area). 
c) Auditory Area: By the cortical branch of the middle cerebral artery. 
d) Visual Area: By the occipital branch of the posterior cerebral artery. 
e) Speech Area: Both motor and sensory, by the cortical branches of the 
middle cerebral artery. 
2. Midbrain: the branches from the posterior cerebral arteries supply 
Midbrain, including   their central branches, both postero-medial and postero-
lateral. 
3. Pons: By the pontine branches of the basilar arteries. 
4. Medulla: By the Medullary branches of the vertebral artery and branches  
from the posterior inferior cerebellar artery. 
5. Cerebellum: By the superior cerebellar artery is a branch of basilar artery 
and the posterior inferior cerebellar artery a branch of vertebral artery. 
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6. Internal Capsule: It is supplied by the central branches of: 
a. Middle cerebral artery, the lenticulo striate branches; 
b. Anterior cerebral artery, the Heubner’s recurrent branch; 
c. Posterior communicating artery 
d. Anterior choroidal artery 
7. Corpus Striatum: 
a. It is supplied chiefly by the anterolateral central branches of the middle 
cerebral artery  
b. Partly by the antero-medial branches from the anterior cerebral and 
anterior communicating arteries. 
8. Thalamus: 
a. Is supplied chiefly by the postero-medial and postero-lateral central 
branches of the posterior cerebral artery and 
b. Partly by the antero-medial central branches. 
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Anatomical Peculiarities of Cerebral Arteries: 
a. The free anastomoses of the circle of Willis equalize pressure in the arteries 
of the two sides. 
b. The presence of the blood brain barrier permits a selective passage of the 
blood contents to the nervous tissue and thus the toxic and harmful 
substances are ordinarily prevented from reaching the brain. 
c. Central branches of the cerebral arteries are end arteries. Thrombosis of any 
one of them therefore will cause infarction. The cortical branches  
establishing poor anastomoses with each other cannot compensate for any 
loss of blood supply to a particular area of the cortex.3,4 
 
 
 
 
 
 
 
 
 
9 
 
 
REGULATION OF CEREBRAL BLOOD FLOW  
 Regulation is by;  
1 Autoregulation 
2 Chemical factors 
3 Neural factors 
 
 
Parameter Value 
CBF(cerebral blood flow)   
 Global 45-55 ml/100 gm/min 
Cortical (mostly grey matter) 75-80 ml/100 gm/min 
Sub cortical (mostly white matter) Approx. 20 mL/100 gm/min 
CMRO (Cerebral Metabolic rate for oxygen) 3-3.5 mL/100 gm/min 
CVR (Cerebral Vascular resistance) 1.5-2.1mm Hg/100 gm/min/ml 
Cerebral Venous PO2 35-40 mm of Hg 
ICP (intracranial pressure)  8-12 mm of Hg 
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 AUTOREGULATION  
           Brain regulates its own blood flow by means of autoregulation. It 
depends on effective perfusion pressure and Cerebral Vascular Resistance. 
Cerebral blood flow depends on the balance between effective perfusion 
pressure and the vascular resistance in brain.  
EFFECTIVE PERFUSION PRESSURE  
          It is the balance between mean arterial pressure and venus pressure 
across the organ divided by resistance. As venus pressure is zero in brain mean 
arterial pressure plays an important role in regulating cerebral blood flow. Auto 
regulation is possible if mean arterial pressure is within the range of 60 – 
140mm Hg. Auto regulation seems to be due to Intrinsic feature of Cerebral 
smooth muscles (myogenic)  
CEREBRAL VASCULAR RESISTANCE  
                 The blood flow to brain decreases if resistance is more. Resistance to 
blood flow is by Intracranial pressure, CSF pressure & viscosity of blood.  
Increase in the Intracranial pressure or CSF pressure tend to decrease cerebral 
blood flow. These pressures are elevated in Head injury. But severe Ischemic 
effects due to head injury are avoided by protective reflexes such as Cushing 
reflex. Cushing reflex is a protective reflex that protects the brain tissue during 
periods of decreased cerebral blood flow. Compression of cerebral blood 
vessels decreases the blood flow to vasomotor centre resulting in local hypoxia 
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and hypercapnea leading to activation of the centre resulting in peripheral 
vasoconstriction and rise in arterial blood pressure. This helps to restore the 
cerebral blood flow.  
MUNRO KELLIE DOCTRINE  
                This states that though the cerebral arteries are compressed by 
increased intracranial pressure or CSF pressure, the volume of brain tissue is 
not affected, since brain tissue is non-compressible.  
VISCOSITY 
                Viscosity of blood influences cerebral blood flow by increase in 
viscosity leading to increased cerebro vascular resistance and decreased blood 
flow. Eg: Polycythemia. Hence in anaemia cerebro vascular resistance is 
reduced both due to decreased viscosity and reduced oxygen carrying capacity 
of blood. Thus adequate oxygen delivery in presence of cerebral Ischemia is 
provided by a hematocrit of 30-35%  
CHEMICAL REGULATION OF CEREBRAL BLOOD FLOW  
              Chemical factors that regulate the blood flow are PaO2, PaCo2& H+ 
concentration. CO2 is the most important factor as it causes dilation of cerebral 
blood vessels leading to increased cerebral blood flow. For each 1mm Hg 
change in PaCO2 changes CBF by 1-2ml/100gm of brain tissue/minute. This 
response decreases if PaCO2 is below 25mm Hg. As CO2 diffuses rapidly  
through the cerebro vascular endothelium changes in CBF caused due to 
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PaCO2 also occurs rapidly.  But a moderate increase in PaCO2 does not alter 
the blood flow due to autoregulation.  
PaO2 
         Hypoxia increases cerebral blood flow by vaso dilatation.  CBF increases 
when PaO2 falls less than 60mm Hg. PaO2 in the range of 60-300 Hg has 
minimal influence on CBF. High PaO2 values decreases CBF minimally.  
NEUROGENIC REGULATION OF CEREBRAL BLOOD FLOW  
          Neurological influence tend to be high on larger cerebral arteries. 
Innervations declines directly with the vessel size. Cerebral blood vessels are 
supplied by sympathetic vaso constrictive fibres. But these fibres do not play 
any role in regulating CBF under normal conditions. In pathological conditions 
like hypertension these sympathetic nerves cause constriction of blood vessels 
leading to reduction in blood flow.  Thus it prevents cerebro vascular 
hemorrhage and cerebral stroke.  
CEREBROVASCULAR RESISTANCE(CVR) 
           It depends on  
1. Pressure within the cranium  
2. Viscosity of blood  
3. Patency of cerebral blood vessels 
4. PaCO2 
5. PaO2 
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6. Adrenaline & Nor-Adrenaline  
7. Ethanol 
PHYSIOLOGY OF CEREBRAL ISCHEMIA  
Cerebral infarction consists of  
1. Decreased oxygen and glucose supply  
2. Alteration of cellular metabolism 
The oxygen stores in brain are very minimal but it can derive its energy 
only from oxidative metabolism of glucose. Hence when CBF decreases 
various functional and neurophysiological changes dependant on glucose 
metabolism occurs at various thresholds of flow. Cerebral metabolism is 
measured by PET scan based on cerebral metabolic rate of glucose and oxygen.  
Oxygen extraction fraction (OEF)v is the same throughout the brain tissue. In 
normal human brain CMRO2 reflex cerebral blood flow. During Ischemia OEF 
increases and CMRO2 falls. These changes are seen early after acute ischemic 
stroke.  
        When the flow is restored quickly functional recovery is possible.  As of 
now lactate accumulates due to anaerobic metabolism of glucose leading to fall 
in ATP synthesis and pH. Cellular transport and neuro transmission also fails. 
Release of platelet activating factor occurs which is also neuro toxic.  
         If flow falls further infarction occurs and function does not recover. By 
this stage CMRO2 and CBF are low and OEF is normal which indicates 
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decreased metabolic activity. Duration of Ischemia and depth of Ischemia 
determines the consequences of fall in CBF. Due to collaterals flow is never 
zero in localised ischemia. CBF is also influenced by cerebral oedema and 
raised ICP. Vaso dilators are acid metabolites and increased extracellular 
potassium concentrations. Vasoconstrictors are prostaglandins released from 
platelets and cell membranes. Metabolic effects of ischemia are increased by 
high glucose concentration.  Seizures may occur due to raised lactate levels. 
Ischemic brain also demonstrates decreased responses to changes in PaCO2 & 
PaO2 and impaired autoregulation.  
RISK FACTORS FOR STROKE  
   Major 
1. Age  
2. Hypertension  
3. Sex 
4. Family history 
5. Cardiac Co-morbidities 
6. History of TIA 
7. History of smoking  
8. Fibrinogen level 
9. Hematocrit level  
10. Abnormal hemoglobins  
11. Cocaine abuse  
12. Diabetes  
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Others 
1. Oral Contraceptives use  
2. Lifestyle pattern  
3. Obesity 
4. Hyperlipidemia 
5. Hyperuricemia 
6. Infections  
7. Increased homocysteine levels 
8. Race 
9. Alcoholism 
10. Peripheral vascular disease  
UNMODIFIABLE RISK FACTORS 
1. Age of the individual 
2. Sex  
3. Race  
4. History of previous stroke  
MODIFIABLE RISK FACTORS  
1. Hypertension  
       Hypertension is the second most powerful risk factor for Ischemic 
stroke after age both SBP & DBP are important. Fall in Diastolic BP by 
6mm Hg decreases incidence of stroke by 40%. 
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2. Myocardial Infarction  
        Transneural Infarcts poses higher risk for stroke than sub 
endocardial infarcts. Previous history of MI is also considered to be a 
risk factoe for stroke. Risk of stroke doubles in presence of cardiac 
disease. Cardiac failure, coronary Heart Disease and Angina increases 
the risk of stroke. 
  
3. Diabetes Mellitus 
               Impaired glucose tolerance  and elevated HbA1C are found to be 
in 40-50% of patients with cerebral infarct who were not known diabetics.  
4    .TIA 
      Previous history of TIA increases the risk of stroke. 
5.SMOKING 
  Studies have proved that risk of stroke doubles in smokers. 
Smoking cessation   reduces the risk of stroke within next two years. 
6.Alcohol  
   Effects of alcohol depends on its pattern of intake. Chronic 
minimal intake decreases stroke incidence whereas acute alcohol binge 
drinking leads to increased risk of cerebral infarction. 
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7.Lipids  
  Studies have proved a weak association between total cholesterol 
and incidence of atherothrombotic brain infarct. 
8.Exercise 
          Risk of stroke increases in women with sedentary lifestyle. 
 
OUTCOME OF STROKE 
Demographic factors 
Age 
Secondary complications including bed sores and pneumonia are 
increased in elderly with stroke. Hence age has a negative influence on 
outcome of stroke. 
Gender 
              Males with stroke have a poor outcome compared to females 
since endogenous estrogens are found to be neuroprotective. 
RISK FACTORS    
               Previous history of stroke and atrial fibrillation are associated 
with poor outcome. 
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CLINICAL FINDINGS 
Consciousness and Gaze deviation 
Presence of gaze deviation and decreased consciousness are associated 
with poor outcome 
Blood pressure     
Both hyper and hypotension are deleterious to brain prenchyma. 
Hypotension decreases flow whereas hypertension can cause hemorrhagic 
transformation. 
Temperature         
Rise in temperature increases the levels of excitotoxic neurotransmitters 
Hence 1*  C rise of temperature is associated with two fold increase in relative 
risk for poor outcome. 
COURSE OF THE ILLNESS AND PROGNOSIS 
                     The course of cerebral thrombosis is unpredictable that it may 
progress and worsen the clinical status as time progresses. Progression is 
mostly due to extension of mural thrombus. The thrombus may extend and 
occlude the anastomotic branches. Basilar artery thrombus may extend along 
its entire length and Carotid thrombus may extend into anterior cerebral artery 
and prevent flow from opposite side. 
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                  Embolic particles from occluded site may propagate and precipitate 
an abrupt change. Large infarcts may compress the adjacent structures leading 
to tentorial herniation after days. Inferior cerebellar infarcts may cause fatal 
foramen magnum herniation.40% mortality is seen in large basilar infarct with 
deep coma.it is 3% to 5% with smaller infarcts. 
                   If coma or stupor develops further focus of care has to be on 
preventing bed sores, Aspiration, Controlling Brain edema, Patency of airway, 
maintaining fluid and electrolyte balance. 
                  Stroke evolves characteristically with flaccid muscles for initial few 
days. Then gradually spasticity develops and tendon reflexes become brisk. 
Initially the patient may assume a posture with flexed adducted upper limbs 
and extended lower limbs. With slow evolution of spasticity the functional 
recovery may be delayed and may not be complete. 
                 Whereas early development of spasticity or early grasp reflex 
favours a quick and better outcome. Patients may remain hemiplegic in 
extensive temporoparietal lesions. Stroke involving thalamus and lentiform 
nucleus incompletely are associated with hemitremors and hemiataxia and 
hemi choreoathetosis. Physiotherapy plays a major role in avoiding 
contractures. 
         Recurrent epileptic seizures are more common in embolic cortical infarcts 
compared to thrombotic strokes. Left frontal lobe infarcts are associated with 
fatigability and reactive depression. 
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         Patients developing thrombotic strokes are prone to develop future similar 
episodes particularly if hypertensive and diabetic.Multiple infarcts over years 
may lead to multi infarct dementia.  
TREATMENT ASPECTS 
Medical treatment available are to decrease the area of infarct and to 
avoid the adverse effects of increased ICP. Thrombolysis are used in higher 
centres  and anti platelets are used as additives later. Mannitol and oral glycerol 
are used to reduce the cerebral edema. Other supportive treatments are to 
reduce the incidence of secondary complication 
URIC ACID  
Uric acid is a heterocyclic compound of carbon, nitrogen, oxygen and 
hydrogen with the formula C5H4N4O3.  Uric acid is a product of metabolic 
breakdown of purine nucleotides. 
Pathophysiological effects of uric acid keeps on evolving as its role in 
gout in older days to role in metabolic syndromes recently.The major source of 
uric acid is its endogenous production .one third are from dietary purines. Uric 
acid is less soluble and 70% is excreted via kidneys. 
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PATHOPHYSIOLOGY  
Hyperuricemia occurs due to either overproduction or decreased 
excretion or both.  Decreased excretion contributes to most cases. 
URIC ACID  -  URATE +  H+ 
Most uric acid in circulation are in the form of urate anion.  Most 
mammalian species have low levels of uric acid since it has been converted to 
allantoin by uricase enzyme. Humans lack the gene expression for uricase 
enzyme leading to levels around 7 mg/dl. Normal adult males have twice the 
levels of female urate levels. Normally daily turnover of 60% of the urate pool 
occurs in humans. 
  Uric acid in the blood is saturated at 6.5 to 6.9 mg/dl. Upper limit of 
solubility is around 7mg/dl. It is freely filtered at glomerulus and gets 
reabsorbed in proximal tubules. It  also gets secreted in proximal tubules. uric 
acid secretion in tubules parallels with the serum levels. Thus higher serum 
levels are associated with marked increase in excretion. 
Decreased excretion may be due to decreased filtration at glomerulus or 
secretion at proximal tubules or increased reabsorption at tubules. Decreased 
excretion contributes to hyperuricemia of kidney disease. Acidotic conditions 
like DKA, SALICYLATE OVERDOSE, STARVATION KETOSIS, 
ALCOHOL IC EXCESS leads to decreased tubular secretion of uric acid. 
These organic acids compete with uric acid for its secretion. Patients on 
diuretic therapy or with Diabetes insipidus exhibit enhanced reabsorption of 
uric acid at site distal to its secretion. 
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               Hyperuricemia due to overproduction may be due to dietary excess of 
purines or increased breakdown of purine nucleotides. Small proportion of 
overproducers have enzymatic defects that account for their hyperuricemia. 
They include Hypoxanthine guanine phosphoribosyl transferase deficiency as 
in leisch nyhan syndrome which exhibits complete deficiency of the enzyme 
whereas partial deficiency leads to Kelly Seegmiller sydrome. Increased purine 
breakdown is seen in rhabdomyolysis, cytotoxic therapy, blast crisis of 
leukemias. Alcohol consumption contributes to both overproduction and 
decreased excretion by increased breakdown of ATP and decreased excretion 
due to organic acids that compete with uric acid for excretion. 
              Other causes include Glycogenoses type I and Aldolase – B deficiency 
that also cause increased production and decreased excretion. 
URIC ACID AS AN ANTI OXIDANT 
              Uric acid plays a role as an anti oxidant but is also a marker of 
oxidative stress.like ascobate it also acts as a peroxidant.It is proposed that 
hyperuricemia induced oxidative stress plays a roll in etiology of stroke 
,atherosclerosis and metabolic syndrome. Ischemia followed by recirculation 
results in freeradical production. Its production can also occur at low tissue  
oxygen tension due to accumulation of reduced compounds. 
          Xanthine  Oxidase is the source of free radicals in reperfusion injury 
.Ischemia promotes the conversion of Xanthine dehydrogenase to Xanthine 
oxidase. This conversion is also enhanced by increased calcium levels. Nitric 
23 
 
oxide also acts as a source of free radical.rising calcium levels in tissues 
stimulates nitric oxide synthetase. 
         Uric acid once considered to be inert is now associated with Gout and 
Xanthinuria. It acts as an antioxidant by reacting with hydroxyl radicals and 
hypochlorous acid. Uric acid also preserves the vasodilation by endothelium in 
situations of oxidative stress. 
 
SERUM URIC ACID IN STROKE 
 Hypertension And Uric Acid 
Uric acid plays a major role in both in pathophysiology of Hypertension. 
1. 25% of newly detected hypertensives have an elevated serum uric acid levels. 
2. Hypertension leads to decreased renal blood flow which in turn leads to 
increased urate absorption. 
3. Hyperuricemia on chronic basis leads to renal injury  leading to hypertension. 
4. Uric acid stimulates macrophage infiltration of atherosclerotic vessels. 
5. Uric acid in raised levels also leads to inhibition of nitric oxide. 
FREE RADICAL INJURY IN CEREBRAL ISCHEMIA  
Free radical mediated injury plays a major role in pathogenesis of 
infarct. Free radicals are liberated from dysfunctional mitochondria, 
inflammatory cells and excitotoxic mechanisms due to increased glutamate and 
aspartate levels. 
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  Superoxide and hydroxyl radicals play a major role in injury by causing 
lipid peroxidation that damages mitochondrial and cell membranes. Lipid 
peroxidation disrupts enzymes ,receptors and various transporters. Thus local 
oxidants increase infarct size and injury. 
  As uric acid plays a role as an anti oxidant  it is expected that elevated 
levels are beneficial but studies have proved that high uric acid levels are 
deleterious and are not beneficial. Reason is uric acid tend to act as a pro 
oxidant in the absence of other anti oxidants like ascorbate. Thus reduced 
ascorbate levels converts uric acid into a pro oxidant rather than as an anti 
oxidant. 
  Consistent with this hypothesis it is observed that high uric acid and low 
ascorbate levels are associated with a poorer outcome. 
ENDOTHELIAL DYSFUNCTION 
Uric acid promotes LDL-C oxidation in vitro and also stimulates 
granulocyte adherence to endothelium. Raised uric acid levels are associated 
with raised inflammatory markers. Uric acid crystallise and gets accumulated 
within atherosclerotic plaques. 
METABOLIC SYNDROME 
Serum uric acid is also associated with increased incidence of metabolic 
syndrome. Both hyperuricemia and metabolic syndrome are related to 
underlying insulin resistance. 
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Metabolic syndrome is associated with insulin resistance and reduced 
insulin induced uricacid excretion leading to hyperuricemia. Insulin resistance 
is linked to increased purine synthesis and thus leading to hyperuricemia. 
Serum uric acid also plays a role in endothelial dysfunction and insulin 
resistance.Uric acid decreases the bioavailability of nitric oxide but nitric oxide 
is needed for glucose  uptake.Thus hyperuricemia leads to insulin resistance. 
 
URIC ACID AND RENAL DYSFUNCTION 
Apart from causing  Metabolic syndrome Hyperuricemia is also found to 
be associated with progressive renal dysfunction which is also proved in rat 
model experiments.GFR<60 ml and albuminuria are associated with metabolic 
syndrome  for which the mechanism remains unclear. Obesity is mentioned as 
a causative factor. Obesity is a component of metabolic syndrome which is 
associated with causing renal dysfunction in various ways. Obesity causes 
glomerular sclerosis . It also causes fat deposition in renal medulla thereby 
tubular flow decreases resulting in volume overload  and hypertension. 
Metabolic syndrome also causes release of cytokines causing endothelial 
dysfunction and oxidative stress. Dyslipidemia caused by raised uric acid levels 
also causes interstitial injury to the kidneys. Thus raised uric acid levels by 
causing metabolic syndrome contributes to development of Chronic Kidney 
Disease. 
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URIC ACID AND GOUT 
Gout is a form of arthritis inflammatory in nature caused due to 
deposition of urate crystals within the joints and periarticular tissues. It occurs 
when high levels of uric acid remains in the serum without excretion which 
causes its crystallisation. Arthritis is an inflammatory response to the 
deposition of needle shaped crystals within the joint cavities and surrounding 
tissues. It is associated with tender, erythematous and swollen joints. Pain 
would be intense initially and later it persists for days to weeks. Person 
susceptible to the development of Gout are  
• Obese 
• Renal involvement 
• Excess alcohol exposure 
• Persons on diuretics 
• Family h/o gout 
• Exposure to lead 
DIAGNOSIS can be confirmed by joint fluid aspirate and demonstration of 
urate crystals in the sample.Blood tests can be misleading since mostly during 
attacks of pain levels of uric acid remains within normal range and it is 
proposed that attack is precipitated due to sudden changes in levels causing 
crystallisation.Thus fluctuation in levels of uric acid is the key determinant in 
precipitating attacks. 
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TREATMENT is by drugs to lower the levels of uric acid. Gout cannot be 
cured but it can be better maintained with drugs. Patient has to be on drugs 
throughout his life which decreases their symptoms and risk of deformity or 
disability. Pain can be managed with NSAIDS which tend to reduce the 
inflammation and provide relief. Colchicine also reduces pain effectively if 
taken within 12 hours of initiation of attack and later to avoid future attacks it 
can be taken in lower doses. Life style modifications like Exercise and Diet 
adjustments also plays a role in prevention of future attacks. Patients are 
advised to have less purine containing foods and to avoid mushrooms, meat, 
asparagus and beans which has high purine content. Patients are also advised to 
stop alcohol as it raises the levels of uric acid and suggested to have plenty of 
water.If left untreated can lead to permanent damage of kidneys and joints.  
There are atleast three inherited defects causing early development of 
Hyperuricemia and Gout: 
• Glucose 6-phosphatase deficiency – VON GIERKE DISEASE 
• Hypoxanthine –Guanine phosphoribosyl transferase deficiency(partial 
and severe) –LESCH NYHAN SYNDROME(severe) 
• Raised 5’phosphoribosyl-1’-pyrophosphate synthetase activity  
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REDUCTION OF URIC ACID AND PROTECTION AGAINST 
STROKE 
Drugs acting to reduce uric acid levels do so by inhibiting Xanthine 
oxidase or increasing excretion of uric acid like probenecid, sulfinpyrazone. 
Other drugs like losartan, fenofibrates, and statins also reduces uric acid levels.       
The findings of LIFE study (Losartan Intervention for Endpoint 
Reduction in hypertension study) suggest that a decrease in Serum uric acid 
induced by losartan treatment attenuates CV risk, including stroke.80 
          Asterios Karagiannis et al81 studied consecutive patients (n=435) 
presenting with ischemic stroke and intracerebral hemorrhage and concluded 
that Elevated levels of Serum uric acid are independently associated with an 
increased risk of early death in acute stroke. 
           Newman EJ, et al 82 studied a cohort of type 2 diabetes patients 
presenting to their unit with computed tomography-confirmed acute stroke. 
Concluded that elevated urate concentration is significantly and independently 
associated with increased risk of future vascular events in diabetic stroke 
patients. Further studies to elucidate the mechanism of this observation are 
required. 
          Christopher J. Weir, et al52 studied 3731 patients with ischemic stroke or 
primary intracranial hemorrhage, and determined the association of urate level 
with 90-day placement (alive at home, good outcome; dead or living in care, 
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poor outcome) and concluded that independent of other prognostic factors, 
higher serum urate levels predicted poor outcome (dead or in care) and higher 
vascular events. 
          Antonio Cherubini et al55 studied antioxidant profile in patients with 
acute ischemic stroke of recent onset (<24 hours) and concluded that patients 
with the worst early outcome (death or functional decline) had higher vitamin 
A and uric acid plasma levels and lower vitamin C levels and erythrocyte super 
oxide dismutase activity than those who remained functionally stable. 
 
 
 
 
  
  
 
 
 
MATERIALS AND 
METHODS 
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MATERIALS AND METHODS 
SOURCE OF DATA 
Patients admitted as in patients at Department of Medicine, MADRAS 
MEDICAL COLLEGE & RAJIVGANDHI GOVT GENERAL HOSPITAL, 
CHENNAI with acute ischemic stroke during the3 period of APRIL 2016 to 
SEPTEMBER 2016 were taken for study considering the inclusion and 
exclusion criteria. 
METHODS OF COLLECTION OF DATA 
 Information was collected from each patient through a printed proforma 
meeting the objectives of the study. Purpose of the study was carefully 
explained to patients and consent was taken. 
Qualifying patients underwent detailed history, clinical examination, 
investigations and followed up for a period of 7 days. Serum uric acid was 
measured when the patient  was admitted. Clinical outcome in terms of 
mortality and physical disability was assessed as per GLASGOW OUTCOME 
SCALE{GOS} which is: 
1. Indicates death 
2. Vegetative state(unable to interact with environment) 
3. Severe disability(unable to live independently but  can follow commands) 
4. Moderate disability(capable of living independently but unable to return to 
work) 
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5. Mild or no disability(patient can return to work) 
TYPE OF STUDY   
          Single centre observational prospective hospital based time bound study. 
 SAMPLING 
          Hospital statistics show that about 400 cases (average) of acute stroke 
were 
          Admitted to MMC&RGGGH in the year2016.the number of case after                           
INCLUSION CRITERIA 
1. Patients who were admitted with first episode of acute ischemic 
stroke with CT evidence of infarction  
EXCLUSION CRITERIA 
1. Patients with subarachnoid hemorrhage, extra dural hemorrhage, sub 
dural hemorrhage and intra cerebral hemorrhage on CT. 
2.  Patients with previous history of TIA/RIND. 
3.  Patients with gout 
4. Patients taking drugs causing hyperuricemia. 
5. Patients who were alcoholics. 
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Such cases of acute ischemic stroke satisfying inclusion and exclusion 
criteria admitted in medical wards of  MMC&RGGGH from March 2016 to 
August 2016 were taken for study as time bound study. 
STATISTICAL ANALYSIS 
SPSS statistical software was used to analyse data.MS office word and 
MS Excel programmes were used to make charts ,ratios 
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RESULTS 
AGE DISTRIBUTION 
Table 1: Age Distribution of Subjects 
AGE_GROUP FREQUENCY PERCENT 
40-50 years 18 30.0 
3451-60 years 15 25.0 
61-70 years 20 33.3 
71-80 years 5 8.3 
>80 years 2 3.3 
Total 60 100.0 
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Descriptive 
Statistics 
N Minimum Maximum Mean Std. Deviation 
AGE_ 60 40.00 84.00 59.2167 11.17365 
 
In this prospective study, majority of stroke patients were between 61 to 
70 years old(33%) whereas 40 to 50 years age group constituted 30%  of study 
population. 
  
35 
 
Fig:1 
Age Distribution 
Thus in our study patients of 41 to 90 years were included and the 
observations made were analysed and depicted. 
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Table: 2 
AGE DISTRIBUTION ACCORDING TO SEX 
AGE_GROUP * SEX 
CROSSTABULATION 
SEX 
Total 
FEMALE MALE 
Age_Group 
40-50 years 
Count 2 16 18 
% within 
SEX 
33.3% 29.6% 30.0% 
51-60 years 
Count 2 13 15 
% within 
SEX 
33.3% 24.1% 25.0% 
61-70 years 
Count 1 19 20 
% within 
SEX 
16.7% 35.2% 33.3% 
71-80 years Count 1 4 5 
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% within 
SEX 
16.7% 7.4% 8.3% 
>80 years 
Count 0 2 2 
% within 
SEX 
0.0% 3.7% 3.3% 
Total 
Count 6 54 60 
% within 
SEX 
100.0% 100.0% 100.0% 
 
Pearson Chi-Square =1.543p=.819 
Majority of males are in 61 to 70 years age group. 
Majority of females are in 41 to 60 years age group. 
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TABLE:3 
RISK FACTORS 
 N Y 
SHT 
Count 18 42 
Table N % 30.0% 70.0% 
D_M 
Count 46 14 
Table N % 76.7% 23.3% 
SMOKING
Count 53 7 
Table N % 88.3% 11.7% 
DYSLIPID
EMIA 
Count 53 7 
Table N % 88.3% 11.7% 
CAD 
Count 53 7 
Table N % 88.3% 11.7% 
Hypertension constituted the major risk factor in this stroke population as 70% 
were hypertensive. 
Diabetes Mellitus ranked second as a risk factor constituting 14% of the 
population. 
Smoking ; Dyslipidemia ;Coronary Artery Disease constituted to 11.7% of the 
population each.  
 Thus Hype
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Table:4 
RISK FACTORS ACCORDING TO GENDER OF THE PATIENT 
FEMALE MALE 
SHT 
Count 4 38 
Table N % 6.7% 63.3% 
D_M 
Count 2 12 
Table N % 3.3% 20.0% 
SMOKING 
Count 0 7 
Table N % 0.0% 11.7% 
DYSLIPIDEMIA 
Count 2 5 
Table N % 3.3% 8.3% 
CAD 
Count 1 6 
Table N % 1.7% 10.0% 
Hereby 63.3% of males are Hypertensives. 
20% of males are Diabetics. 
6.7% of females are Hypertensives. 
Thus majority of males in this stroke population are Hypertensives. 
 RISK 
 
Hypertens
 
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
FACTOR
ion is the l
6.70%
63.30%
S ACCOR
eading risk
 
3.30%
20.00
42
Fig:
DING TO
 factor in 
0.00%
%
11.7
4 
 GENDE
both sexes
3.30%
0%
8.
R OF TH
 of the stu
1.70%
30%
1
E PATIE
dy populat
0.00%
NT 
ion. 
FEMALE
MALE
 
43 
 
TABLE:5 
DISTRIBUTION OF URIC ACID LEVELS 
URIC_ACID_CLASS FREQUENCY PERCENT 
<5 7 11.7 
5-7 12 20.0 
>7 41 68.3 
Total 60 100.0 
 
Descriptive 
Statistics 
N 
Minimu
m 
Maximum Mean Std. Deviation 
URIC_ACID 60 3.50 14.00 8.4550 2.50054 
Valid N 
(listwise) 
60     
Mean serum uric acid value of study population is 8.45 mg/dl. Majority of 
subjects had high serum uric acid levels of >7 mg/dl (68.3%) whereas 20% had 
  
  
 
 
 
 
 
 
 
  
 
 
 
68.3%
uric acid lev
 
44
URIC_A
Fig: 
els within
11.7%
CID_CLA
5 
 the norm
20.0%
SS
al levels. 
<5
7-May
>7
45 
 
TABLE :6 
URIC ACID AND GENDER 
URIC_ACID_CLASS * SEX 
Crosstabulation 
SEX 
Total 
FEMALE MALE 
URIC_ACID_CLAS
S 
<5 
Count 1 6 7 
% within SEX 16.7% 11.1% 11.7% 
5-7 
Count 1 11 12 
% within SEX 16.7% 20.4% 20.0% 
>7 
Count 4 37 41 
% within SEX 66.7% 68.5% 68.3% 
Total 
Count 6 54 60 
% within SEX 100.0% 100.0% 100.0% 
 
Majority of males in the study population have high serum uric acid levels of 
>7mg/dl (68.5%).Majority of females also have high uric acid levels 
of>7mg/dl(66.7%) 
Hence majority of subjects in both sexes havew high serum uric acid levels        
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TABLE 7:  DISTRIBUTION OF AGE GROUPS AND URIC ACID 
LEVELS 
 
                 
Most  of the  persons with high uric acid levels are in the age group 40 to 50 . 
Next is 61 to 70 years group and 51 to 60 years group. 
 
 
URIC_ACID_CLASS * 
age_group Crosstabulation 
AGE_GROUP 
Total 40-50 
years 
51-60 
years 
61-70 
years 
71-80 
years 
>80 
years 
URIC_ACI
D_CLASS 
<5 
Count 1 2 4 0 0 7 
% within 
age_group 5.6% 13.3% 20.0% 0.0% 0.0% 11.7%
5-7 
Count 3 3 4 2 0 12 
% within 
age_group 16.7% 20.0% 20.0% 40.0% 0.0% 20.0%
>7 
Count 14 10 12 3 2 41 
% within 
age_group 77.8% 66.7% 60.0% 60.0% 100.0% 68.3%
Total 
Count 18 15 20 5 2 60 
% within 
age_group 
100.0
% 
100.0
% 
100.0
% 100.0% 100.0% 
100.0
% 
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TABLE:8 
AGE GROUPS WITH MEAN URIC ACID LEVELS 
 N Mean 
Std. 
Deviation 
Std. 
Error 
95% Confidence Interval 
for Mean 
Lower 
Bound 
Upper 
Bound 
40-50 
years 
18 8.8333 2.16251 .50971 7.7579 9.9087 
51-60 
years 
15 8.6733 3.02170 .78020 7.0000 10.3467 
61-70 
years 
20 7.6450 2.23477 .49971 6.5991 8.6909 
71-80 
years 
5 8.7000 2.16795 .96954 6.0081 11.3919 
>80 years 2 10.9000 4.38406 3.10000 -28.4892 50.2892 
Total 60 8.4550 2.50054 .32282 7.8090 9.1010 
 
F=1.159 P=0.339 NON SIGNIFICANT  
There is no significant difference between age and serum uric acid levels. 
 
 
50 
 
TABLE :9 
GENDER WITH MEAN URIC ACID 
 
 
 SEX N Mean Std. Deviation Std. Error Mean 
URIC_ACI
D 
MALE 54 8.5333 2.50742 .34122
FEMALE 6 7.7500 2.54460 1.03883
t=0.725 P=0.471 NON SIGNIFICANT 
There is no significant difference in males and females in uric acid levels. 
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TABLE :10 
HYPERTENSION WITH MEAN URIC ACID 
 
Group Statistics 
  
SHT N Mean 
Std. 
Deviation
Std. 
Error 
Mean 
t value
p 
value 
URIC_ACID 
PRESENT 42 8.5762 2.50734 .38689 
.570 .571 
ABSENT 18 8.1722 2.53326 .59710 
 
There is no significant difference between serum uric acid levels and 
hypertension. 
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TABLE:11 
DIABETES WITH MEAN URIC ACID 
D_M N Mean 
Std. 
Deviation
Std. 
Error 
Mean 
t value p value 
URIC_ACID 
PRESENT 14 8.2571 2.87903 .76945 
-.336 .738 
ABSENT 46 8.5152 2.40573 .35471 
 
There is no significant difference between diabetes and serum uric acid. 
  
53 
 
TABLE:12 
SMOKING WITH MEAN SERUM URIC ACID 
SMOKING N Mean 
Std. 
Deviation
Std. 
Error 
Mean 
T value p value
URIC_ACID 
PRESENT 7 6.9000 2.06236 .77950 
-1.783 .080 
ABSENT 53 8.6604 2.49702 .34299 
 
There is no significant difference between smoking and serum uric acid. 
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TABLE:13 
DYSLIPIDEMIA WITH MEAN URIC ACID 
DYSLIPIDEMIA N Mean 
Std. 
Deviation
Std. 
Error 
Mean 
t value p value 
URIC_ACID 
PRESENT 7 8.2143 1.91174 .72257 
-.269 .789 
ABSENT 53 8.4868 2.58145 .35459 
 
There is no significant difference between dyslipidemia and serum uric acid. 
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TABLE:14 
CORONARY ARTERY DISEASE WITH MEAN URIC ACID 
CAD N Mean 
Std. 
Deviation
Std. 
Error 
Mean 
t value p value 
URIC_ACID 
PRESENT 7 8.1143 3.12380 1.18068 
-.381 .705 
ABSENT 53 8.5000 2.43942 .33508 
  
There is no significant difference between coronary artery disease and uric 
acid. 
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TABLE:15 
ARTERIAL TERRITORY WITH MEAN URIC ACID 
 N Mean 
Std. 
Deviation 
Std. 
Error 
95% Confidence Interval for 
Mean 
Lower 
Bound 
Upper Bound 
MCA 37 8.8784 2.71336 .44607 7.9737 9.7831 
PCA 5 9.0000 1.27475 .57009 7.4172 10.5828 
ACA 8 7.2250 1.41093 .49884 6.0454 8.4046 
PCA+M
CA 
7 7.1429 1.90863 .72139 5.3777 8.9080 
ACA+M
CA 
3 8.6667 3.81881 2.20479 -.8198 18.1531 
Total 60 8.4550 2.50054 .32282 7.8090 9.1010 
F=1.324 P=0.272 NON SIGNIFICANT. There is no significant difference. 
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TABLE:16 
COMPARISON OF VASCULAR TERRITORY WITH URIC ACID 
CT_EVIDENCETERRITORY * 
URIC_ACID_CLASS 
Crosstabulation 
URIC_ACID_CLASS 
Total 
<5 5-7 >7 
CT_Eviden
ceterritory 
MCA 
Count 3 8 26 37 
% within 
Uric_Acid_Clas
s 
42.9% 66.7% 63.4% 61.7% 
PCA 
Count 0 0 5 5 
% within 
Uric_Acid_Clas
s 
0.0% 0.0% 12.2% 8.3% 
ACA 
Count 1 3 4 8 
% within 
Uric_Acid_Clas
s 
14.3% 25.0% 9.8% 13.3% 
PCA+M Count 2 1 4 7 
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CA % within 
URIC_ACID_C
LASS 
28.6% 8.3% 9.8% 11.7% 
ACA+M
CA 
Count 1 0 2 3 
% within 
URIC_ACID_C
LASS 
14.3% 0.0% 4.9% 5.0% 
Total 
Count 7 12 41 60 
% within 
URIC_ACID_C
LASS 
100.0% 100.0% 100.0% 100.0% 
Pearson Chi Square =8.176 P =0.416 NON SIGNIFICANT  
Hereby vascular territory involved was compared with mean serum uric acid 
and it was found that persons with MCA territory involvement had high uric 
acid levels.  
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TABLE:17 
HYPERTENSION AND GLASGOW OUTCOME SCALE 
CROSSTAB 
GLASGOW_OUTCOME_SC
ALE Tota
l 
1.00 2.00 3.00 4.00 5.00 
SHT 
ABSENT 
Count 1 1 9 4 3 18 
% within 
GLASGOW_O
UTCOME_SCA
LE 
33.3% 7.7%
40.9
% 
22.2
% 
75.0
% 
30.0
% 
PRESEN
T 
Count 2 12 13 14 1 42 
% within 
GLASGOW_O
UTCOME_SCA
LE 
66.7%
92.3
% 
59.1
% 
77.8
% 
25.0
% 
70.0
% 
Total 
Count 3 13 22 18 4 60 
% within 
GLASGOW_O
UTCOME_SCA
LE 
100.0
% 
100.
0% 
100.
0% 
100.
0% 
100.
0% 
100.
0% 
Pearson Chi Square=8.719 P=0.069 
Among 60 persons 42 had hypertension(30%).Among them 12 persons had 
poor GOS OF 2.0 
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TABLE:18 
DIABETES MELLITUS AND GLASGOW OUTCOME SCALE 
CROSSTAB 
GLASGOW_OUTCOME_S
CALE Total 
1.00 2.00 3.00 4.00 5.00 
D_M 
ABSENT 
Count 2 10 17 14 3 46 
% within 
GLASGOW_OUTC
OME_SCALE 
66.7
% 
76.9
% 
77.3
% 
77.8
% 
75.0
% 
76.7%
PRESEN
T 
Count 1 3 5 4 1 14 
% within 
GLASGOW_OUTC
OME_SCALE 
33.3
% 
23.1
% 
22.7
% 
22.2
% 
25.0
% 
23.3%
Total 
Count 3 13 22 18 4 60 
% within 
GLASGOW_OUTC
OME_SCALE 
100.
0% 
100.
0% 
100.
0% 
100.
0% 
100.
0% 
100.0
% 
Pearson Chi Square=0.191 P =0.996 
Among 60 persons 14 had Diabetes. But no significant association was 
found between Diabetes and Glasgow Outcome Scale.  
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TABLE:19 
SMOKING AND GLASGOW OUTCOME SCALE 
CROSSTAB 
GLASGOW_OUTCOME_SC
ALE Total
1.00 2.00 3.00 4.00 5.00 
SMOK
ING 
ABSENT 
Count 3 13 18 16 3 53 
% within 
GLASGOW_OUT
COME_SCALE 
100.0
% 
100.
0% 
81.8
% 
88.9
% 
75.0% 88.3%
PRESEN
T 
Count 0 0 4 2 1 7 
% within 
GLASGOW_OUT
COME_SCALE 
0.0%
0.0
% 
18.2
% 
11.1
% 
25.0% 11.7%
Total 
Count 3 13 22 18 4 60 
% within 
GLASGOW_OUT
COME_SCALE 
100.0
% 
100.
0% 
100.
0% 
100.
0% 
100.0%
100.0
% 
Pearson Chi Square=3.715 P=0.446 
Among 60 persons 7 were smokers. 
But there is no significant association between Smoking and Glasgow Outcome 
Scale. 
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TABLE :20 
DYSLIPIDEMIA AND GLASGOW OUTCOME SCALE 
Pearson Chi Square =1.408 P=O.843 
Among 60 persons 7 had dyslipidemia. 
But there is no significant association between Dyslipidemia and GOS.  
 
 
CROSSTAB 
GLASGOW_OUTCOME_SCALE
Total
2.00 3.00 4.00 5.00 
Dyslipide
mia 
Absent 
Count 3 11 20 16 3 53 
% within Glasgow_ 
Outcome_Scale 
100.0
% 
84.6% 90.9% 88.9% 
75.0
% 
88.3%
Present 
Count 0 2 2 2 1 7 
% within Glasgow_ 
Outcome_Scale 
0% 15.4% 9.1% 11.1% 
25.0
% 
11.7%
Total 
Count 3 13 22 18 4 60 
% within 
Glasgow_Outcome_S
cale 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
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TABLE:21 
CORONARY ARTERY DISEASE AND GLASGOW OUTCOME 
SCALE 
CROSSTAB 
GLASGOW_OUTCOME_SCA
LE Total
1.00 2.00 3.00 4.00 5.00 
CAD 
ABSENT 
Count 2 12 19 17 3 53 
% within 
GLASGOW_OUT
COME_SCALE 
66.7
% 
92.3
% 
86.4
% 
94.4
% 
75.0
% 
88.3
% 
PRESENT 
Count 1 1 3 1 1 7 
% within 
GLASGOW_OUT
COME_SCALE 
33.3
% 
7.7%
13.6
% 
5.6% 
25.0
% 
11.7
% 
Total 
Count 3 13 22 18 4 60 
% within 
GLASGOW_OUT
COME_SCALE 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
Pearson Chi Square =2.991 P=0.559 
Among 60 persons 7 were having Coronary  Artery Disease. 
But there is no significant association between Coronary Artery Disease and 
GOS. 
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TABLE:22 
TERRITORY  INVOLVEMENT AND GLASGOW OUTCOME SCALE 
CROSSTAB 
Glasgow_Outcome_Scale 
Total 
1.00 2.00 3.00 4.00 5.00 
CT_EVIDEN
CETERRITO
RY 
MCA 
Count 3 11 11 9 3 37 
% 
100.
0% 
84.6
% 
50.0
% 
50.0
% 
75.0
% 
61.7%
PCA 
Count 0 1 3 1 0 5 
% 0.0% 7.7%
13.6
% 
5.6% 0.0% 8.3% 
ACA 
Count 0 0 3 4 1 8 
% 0.0% 0.0%
13.6
% 
22.2
% 
25.0
% 
13.3%
PCA+MC
A 
Count 0 0 5 2 0 7 
% 0.0% 0.0%
22.7
% 
11.1
% 
0.0% 11.7%
ACA+MC
A 
Count 0 1 0 2 0 3 
% 0.0% 7.7% 0.0%
11.1
% 
0.0% 5.0% 
Total 
Count 3 13 22 18 4 60 
% 
100.
0% 
100.
0% 
100.
0% 
100.
0% 
100.
0% 
100.0
% 
Pearson Chi Square=15.560  P=0.484 
Among 60 persons 37 were having MCA infarct and persons with MCA infarct 
were prone for poor GOS score. 
But it was not statistically significant. 
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TABLE:23 
AGE GROUP AND GLASGOW OUTCOME SCALE 
CROSSTAB 
GLASGOW_OUTCOME_SC
ALE Tota
l 
1.00 2.00 3.00 4.00 5.00 
SEX 
MALE 
Count 3 12 19 17 3 54 
% 
100.
0% 
92.3
% 
86.4
% 
94.4
% 
75.0
% 
90.0
% 
FEMALE 
Count 0 1 3 1 1 6 
% 0.0% 7.7%
13.6
% 
5.6% 
25.0
% 
10.0
% 
Total 
Count 
Coun
t 
13 22 18 4 60 
% within 
GLASGOW_OU
TCOME_SCALE
% 
100.
0% 
100.
0% 
100.
0% 
100.
0% 
100.
0% 
Pearson Chi Square=22.522 P=0.127 
Among 60 persons 20 were in age group of 61 to 70 years, next is 40 to 50 
years and 50 to 60 years. 
There is no statistical relationship between Age group and GOS. 
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TABLE:24 
SEX DIFFERENCE AND GLASGOW OUTCOME SCALE 
CROSSTAB 
GLASGOW_OUTCOME_SCALE 
Total 
1.00 2.00 3.00 4.00 5.00 
Age_group 
40-
50 
years 
Count 2 2 9 4 1 18 
% 66.7% 15.4% 40.9% 22.2% 25.0% 30.0%
51-
60 
years 
Count 0 6 3 4 2 15 
% 0.0% 46.2% 13.6% 22.2% 50.0% 25.0%
61-
70 
years 
Count 0 4 6 9 1 20 
% 0.0% 30.8% 27.3% 50.0% 25.0% 33.3%
71-
80 
years 
Count 0 1 3 1 0 5 
% 0.0% 7.7% 13.6% 5.6% 0.0% 8.3% 
>80 
years 
Count 1 0 1 0 0 2 
% 33.3% 0.0% 4.5% 0.0% 0.0% 3.3% 
Total 
Count Count 13 22 18 4 60 
% % 100.0% 100.0% 100.0% 100.0% 100.0%
Pearson Chi Square=2.129 P =0.712  
Among 60 persons 54 were males . 
No significant relationship exists between sex and GOS. 
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TABLE :25 
CORRELATION BETWEEN SERUM URIC ACID LEVEL AND GOS 
BY SPEARMAN’S METHOD 
 URIC_ACID 
Spearman's 
rho 
GLASGOW_OUTC
OME_SCALE 
Correlation 
Coefficient 
-.856** 
Sig. (2-tailed) .000 
N 60 
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From the above graph it shows that  as Serum uric acid level raises GOS score 
decreases . Thus the outcome of patients with high serum uric acid levels is 
poor compared to normal or low uric acid levels. 
Hence there is a Negative Correlation between Serum uric acid levels and 
GOS. 
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Model Summaryb 
Mode
l 
R 
R 
Squar
e 
Adjuste
d R 
Square 
Std. 
Error of 
the 
Estimat
e 
Change Statistics 
R 
Square 
Chang
e 
F 
Chang
e 
df
1 
df
2 
Sig. F 
Chang
e 
1 
.871
a 
.758 .754 .49233 .758 
182.03
8 
1 58 .000 
a. Predictors: (Constant), URIC_ACID 
b. Dependent Variable: GLASGOW_OUTCOME_SCALE 
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Coefficientsa 
Model 
Unstandardize
d Coefficients 
Standardize
d 
Coefficients 
t Sig. 
95.0% 
Confidence 
Interval for B
B 
Std. 
Error 
Beta 
Lower 
Boun
d 
Upper 
Boun
d 
1 
(Constant) 6.041 .226  
26.74
6 
.00
0 
5.589 6.493
URIC_ACI
D 
-.346 .026 -.871 
-
13.49
2 
.00
0 
-.397 -.295 
a. Dependent Variable: GLASGOW_OUTCOME_SCALE 
 
With above inferences  GOS can be estimated from Serum uric acid levels 
by the Equation: 
GOS =-0.346(URIC ACID) + 6.041 
Eg: 
If uric acid level is 12 ,then as per equation -4.152+6.041, GOS is 2. 
Hereby we can predict the GOS by using Serum uric acid levels. 
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TABLE:26 
URIC ACID AND GLASGOW OUTCOME SCALE 
gos * URIC_ACID_CLASS Crosstabulation 
 URIC_ACID_CLASS Total 
<5 5-7 >7 
Gos 
bad (1-3) 
Count 0 3 35 38
%  0.0% 7.89% 92.11% 63.3%
good (4-
5) 
Count 7 9 6 22
%  32% 41% 27% 36.7%
Total 
Count 7 12 41 60
% within 
URIC_ACID_CLAS
S 
100.0% 100.0% 100.0% 100.0%
overall 38 (63%) were having bad outcome .among 38 patients 35(92%) were 
having high SUA                   
Thus by our study most of the population have poor GOS and among them 
92% have high serum uric acid levels. 
It is also proved statistically significant and there exists a negative correlation 
between serum uric acid levels and GOS Score. 
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DISCUSSION 
RISK FACTORS 
The risk factors considered in this study are HYPERTENSION, 
DIABETES MELLITUS, CORONARY ARTERY DISEASE, SMOKING and 
DYSLIPIDEMIA.  
Among the risk factors ranking first is Hyperetension contributing about 
70% of the study population which is followed by Diabetes constituting around 
14% of the population. Next ranking risk factors are Smoking, Coronary artery 
disease and Dyslipidemia constituting 11.7% each. 
63% of total male population are Hypertensives.4% of females are 
Hypertensives. 20% of males are Diabetics. 
STUDIES ON INDIVIDUAL RISK FACTORS 
Studies which give the prevalence of various risk factors are mentioned 
below: SERUM URIC ACID AND HYPERTENSION 
Study by Jae Joong Lee(Lee et al.2015), mentioned that in males of less 
than 40 years uric acid association was strong with respect to both Systolic and 
Diastolic pressures. This association was found to be strong in females than 
males. But it was not significant in other age groups . 
Study by R.J.Johnson 2003 dealt with in detail the effects of 
Hyperuricemia on increased cardiovascular morbidity and pathogenesis of 
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Hypertension by renal effects. Serum uric acid was high in males and post 
menopausal females with increased cardio vascular risk.(estrogen is 
uricosuric).Serum uric acid is proved to be associated with endothelial 
dysfunction. 
Wang et al proved the association between high uric acid levels and 
systolic BP. 
Also Chammaro et al proved significant association between BP and 
Raised uric acid levels. 
In our study totally 67% are hypertensives. In both males and females 
Hypertension constitutes the major existing risk factor. But it was not 
statistically significant. Though in all other studies Hypertension is associated 
with increased levels of uric acid ,in our study Hypertension and Raised uric 
acid levels are not statistically significant. 
DIABETES MELLITUS 
 Study by Lehto 1998, in Diabetic patients high uric acid levels are 
significantly associated with stroke incidence and also fatality was proved to be 
on the higher side. 
In NHANES I epidemiologic study,1971-1992  it suggests an 
independent association between raised uric acid levels and increased risk of 
obesity, dyslipidemia and hypertension. Hyperuricemia is also found to be 
associated with Insulin Resistance. 
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Study by Dehghan 2008, suggests that serum uric acid is an independent 
risk factor associated with Diabetes. 
Study by Satoru Kodama 2009,by Meta Analysis proved that Serum uric 
acid level is positively associated with Diabetes excluding other variables. 
In our study , 23% were Diabetics thus constituting second most 
associated risk factor. Though above said studies proved an association 
between Hyperuricemia and Diabetes there was no statistically significant 
association between them in our study. 
SMOKING 
Study by Chammaro et al found no significant association between 
smoking and high uric acid levels. 
In our study,11% were smokers and there was no statistically significant 
association between smokers and high serum uric acid levels. 
DYSLIPIDEMIA 
GREACE study 2004, suggests that serum uric acid levels are an 
independent risk factor for CAD. Hence when started on statin therapy  it 
reduces uric acid levels thereby reducing overall future risk. 
Study by Tsan Yang 2012, suggests an association between 
Hyperuricemia and Metabolic syndrome which is more common in females. 
Sex related association is yet to be studied. 
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Study by Ishizaka 2005, suggests that the prevalence of Metabolic 
syndrome showed gradual increase in incidence as uric acid levels rise. 
In our study 11% had Dyslipidemia and there was no statistical 
significant association between them. 
CORONARY ARTERY DISEASE (CAD) 
Study by Christopher Bickel 2002,suggests that serum uric acid raised 
levels are associated with increased mortality in angiographically proved CAD 
patients. 
The Rotterdam study by J Bos,in his follow up study for 8 years 
suggests that Hyperuricemia is associated with increased risk of Myocardial 
Infarction and Stroke. 
Framingham study by F.N..BRAND, suggests that Hyperuricemia is 
significantly associated with CAD. 
In our study,11% had CAD and it was not in significant association with 
Hyperuricemia. 
PROGNOSIS OF STROKE PATIENTS AND URIC ACID LEVELS 
In various studies mentioned above there exists independent association  
between Hyperuricemia and CAD, DYSLIPIDEMIA, HYPERTENSION, 
DIABETES MELLITUS and METABOLIC SYNDROME. 
78 
 
URIC ACID is considered to be also an Anti oxidant but which is 
proved to have pro oxidant effect in absence of other anti oxidants like 
Ascorbate. 
Uric acid causes Endothelial Dysfunction and also decreases the levels 
of Nitric oxide which contributes the major pathophysiology for vascular 
events. 
Hyperuricemia is found to increase the mortality in Diabetic Stroke 
patients and in aged population incidence of fatal stroke is increased. 
Uric acid elevated levels are significantly associated with atherosclerosis 
and Dyslipidemia. Uric acid causes peroxidation of LDL and increases the 
production of oxygen free radicals. It also increases thrombus formation by 
increasing platelet aggregation. It is also proved that increased levels of uric 
acid crystals are found in atheromatous plaques of patients with high uric acid 
levels. According to Weir et al uric acid was proved to be a predictor of poor 
outcome in stroke patients. Three times risk is found to be associated with high 
uric acid levels. 
Muir study suggests that Allopurinol which is used to treat 
Hyperuricemia decreases the levels of both uric acid and pro inflammatory 
markers. Hence it can be given to reduce future incidence of vascular events. 
Karagiannis study mentioned an independent association between raised 
uric acid levels and stroke based earlier death. 
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European Heart Journal mentions that after an episode of stroke, uric 
acid levels can be used to assess the risk of cardiac deaths in those patients. It 
suggests that high Urate levels were associated with increased risk of cardiac 
death in future. 
Khan et al proved the association between high uric acid levels and 
arterial stiffness. Hereby Hyperuricemics who are stroke survivors are prone 
for developing stiff vessels in near future. 
In our study among 60 persons with stroke, 38 were having bad outcome 
(63%).Among them 35 were having high uric acid levels(92%).Hence our 
study suggests a significant association between high uric acid levels and poor 
GOS. There is no significant association between GOS in stroke patients and 
the associated risk factors like Smoking, Dyslipidemia and CAD in our study. 
Also by Spearman”s correlation method ,it was found that as uric acid 
levels rise GOS score decreases. It was proved in the graph above. There exists 
a negative correlation between uric acid levels and GOS. 
Thus studies around the world suggests association of raised uric acid 
levels with increased incidence of Diabetes, Dyslipidemia and Metabolic 
syndrome. 
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SUMMARY 
Uric acid is well known for its anti oxidant properties and free radical 
scavenging properties. It is also proved that in the absence of other anti 
oxidants like ascorbate it behaves in an opposite manner contributing to pro 
oxidant properties. Hence in our study we were looking at incidence of stroke 
patients with high uric acid levels and prognosis of those with higher values by 
assessing the GOS. 
In our study of 60 patients, males were predominant in number. Age 
difference was not there between both sexes. Other risk factors like 
Dyslipidemia, Smoking, CAD and Hypertension were also taken into account. 
In our study population Mean Uric Acid level was found to be 8.45mg/dl. 
Majority of subjects had higher levels of >7mg/dl whereas 20% had normal 
uric acid levels. 
In our study 38 persons were having poor outcome(63%).Among the 38 
persons 35 were having high uric acid levels(92%).Hence by our study there 
exists a significant statistical association between serum uric acid level and 
GOS at the end of seven days of observation. Both were in negative correlation 
proved by Spearman’s correlation method. 
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CONCLUSION 
Our study of 60 persons included persons suffering from ischemic stroke 
at presentation after fulfilling the exclusion and inclusion criteria mentioned 
above. Other risk factors like Age, Dyslipidemia, Smoking, Diabetes, CAD and 
Sex were taken into consideration. Among these most of the persons were of 
male sex and most of them were Hypertensives. But there was no statistical 
significant association between Male sex, Hypertension and Raised uric acid 
levels. 
          In our study 63% had poor outcome and among them 92% were having 
high uric acid levels. Based on our study it can be said that uric acid levels are 
used to prognosticate the stroke patients on their outcome basis at the end of 
seven days. Uric acid lowering drugs as a therapeutic option in stroke patients 
is in need of future research. 
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PROFORMA 
  
PROFORMA 
“A STUDY OF SERUM URIC ACID AT PRESENTATION AS AN 
INDICATOR OF OUTCOME AMONG ACUTE ISCHEMIC STROKE 
PATIENTS” 
                                              
NAME                                                                        I.P NO. 
 
AGE                                                                OCCUPATION                    
 
SEX                                                                            ADDRESS 
                                              
DATE OF ADMISSION 
SOCIOECONOMIC STATUS 
CHIEF COMPLAINTS ; 
1. 
2. 
3. 
4. 
Seizures: Y / N  
ICT Features; Y / N 
H / O LOC : Y / N 
 
h/s/o higher functions abnormality : 
h/s/o cranial nerve lesions: 
h/s/o motor system abnormalities: 
h/s/o sensory involvement: 
 
PAST HISTORY; 
 HTN-  y/n                            DM –  y/n  
 CAD-  y/n                            CVA-  y/n  
 TIA-  y/n                              Hyperlipidemia – y/n  
 GOUT-  y/n  
 
PERSONAL HISTORY 
SMOKING-   Y/N                                                  ALCOHOLISM;- Y/N 
DIET- Veg/ Non veg/ mixed                                  
 
FAMILY HISTORY; 
DM- ;                             HTN ;   
CAD ;                             TIA ;       
CVA ;                           GOUT 
 
 
 
GENERAL PHYSICAL EXAMINATION; 
Sensorium                               posture 
Built                                        Nourishment 
Spine                                       skull 
 
VITALS; 
PULSE                                      TEMP 
B.P                                             JVP             
R.R 
 
SYSTEMIC EXAMINATION; 
CENTRAL NERVOUS SYSTEM- 
 
HIGHER MENTAL FUNCTIONS; 
    Consciousness; 
      Memory; 
      Speech  
      Behaivour 
 
 
 
 
CRANIAL NERVES EXAMINATION 
 
      RT                                                LT 
OLFACTORY N 
OPTIC N  
   Visual acuity 
    Visual field 
    Colour vision 
    Fundoscopy 
 
III,IV,VI nerves 
   EOM 
   Conjugate movements 
    Saccades 
    Ptosis- Y/N                                          
    Diplopia- Y/N 
  
 PUPILS  
   Size 
    Shape 
    Light reflex 
    Accommodation reflex 
 TRIGEMINAL N 
   Motor 
    Sensory 
    Jaw jerk 
    Corneal reflex 
 
FACIAL N 
    Face appearance 
    Eye closure 
    Forehead wrinkling 
    Taste sensation 
 
VESTIBULOCOCHLEAR N 
    Rinne’s 
    Weber’s 
    Auditory inattention 
 
IX, X Nerves 
     Palatal movements 
    Gag reflex 
 
 
SPINAL ACCESSORY N 
    Sternomastoid 
     Trapezius 
 
HYPOGLOSSAL 
    Tongue movements 
     Wasting  
     Fasciculations 
     Involuntary movements 
 
SIGNS  OF MENINGEAL IRRITATION; 
    Neck stiffness                                 
     Kernig’s sign  
 
MOTOR SYSTEM; 
    UPPER LIMB 
       Nutrition 
       Tone 
       Power 
       Co-ordination 
 
 
LOWER LIMB 
      Nutrition 
      Tone 
      Power 
      Co-ordination 
 
SENSORY SYSTEM 
    Superficial 
            Touch 
            Pain 
            Temp 
 
    Deep 
            Pain 
            Vibration 
            Position 
       Cortical sensations 
 
REFLEXES 
      Superficial 
            Abdominal 
             Plantars 
       Deep 
             Biceps 
             Triceps 
             Supinator 
             Knee 
             Ankle 
 
RHOMBERG’S TEST 
GAIT 
CEREBELLAR SYSTEM; 
AUTONOMIC FUNCTION     
 
OTHER SYSTEMS ; 
(a CVS : 
(b) RS : 
(c) P / A: 
 
  
INVESTIGATIONS; 
1. COMPLETE  HEMOGRAM 
2. B .urea 
   S.creatinine 
3. Blood : Sugar-      mgs/dl 
4. Lipid profile:   TCL        
                             LDL 
                             HDL 
                             TG 
5. Serum uric acid- 
6. ECG in all leads – 
7. CT Brain -   
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